Opportunistic infection highlights from the 35th ICAAC.
Torres
G
G
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology*; D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D000077404:Cidofovir; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D015774:Ganciclovir / Q000627:therapeutic use; D006678:HIV / Q000302:isolation & purification; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000627:therapeutic use; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D011014:Pneumonia / Q000517:prevention & control; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D014481:United States / Q000453:epidemiology; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014766:Viremia
D000998:Antiviral Agents; D001428:Bacterial Vaccines; D007252:Influenza Vaccines; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D014633:Valine; D000077404:Cidofovir; D000077483:Valacyclovir; D015774:Ganciclovir; D000212:Acyclovir